News & Analysis on Clinical Trial Services & Contract Research And Development
As part of an initiative to speed development of new medical products through the science of pharmacogenomics, the Food and Drug Administration (FDA) has issued a final guidance that aims to clarify how pharmacogenomic data will be evaluated.
DrugResearcher two-part special feature
In the second of a two-part interview, DrugResearcher.com spoke to Dr. Tim Jaeger, director of business development at iAS interactive Systems, Germany. Here, Jaeger spoke about the future of knowledge management and commented on the broadening role...
UK speciality chemicals firm C6 Solutions has said that it will be stopping production operations by the end of 2005 and has put its entire manufacturing plant and equipment up for sale.
A study suggesting combination therapy could stop the spread and halt the growth of skin melanomas could pave the way for a better understanding of the disease, and thus, the development of more effective long-term treatment options for patients.
Theravance has announced that GlaxoSmithKline (GSK) has exercised its option to license Theravance's inhaled bifunctional, muscarinic antagonist/beta2 agonist (MABA) program under the terms of their 2004 agreement. The compounds offer great potential...
One of the most chemically benign separation processes could for the first time be made available to manufacturers in the pharmaceutical industry, thanks to pioneering work carried out by researchers in the US.
The world's number one pharmaceutical company, Pfizer, is to close a plant in Michigan, US, as part of a drive to reduce its global manufacturing capacity.
Researchers at the Serono Genetics Institute have announced the identification of 80 genes involved in the inflammatory and neuro-degenerative pathways of multiple sclerosis (MS) forming a library of potential targets for future treatments of the disease.
There is speculation that the problems at GlaxoSmithKline's manufacturing facility in Puerto Rico may prove to be more costly for the company than originally thought.
GE Healthcare has expanded its AKTA range of chromatography amd filtration systems with the launch of AKTAcrossflow for membrane selection and process development at the research scale.